From June 16 to 18, the Shanghai New International Expo Centre successfully hosted the 24th CPHI China and 19th PMEC China 2026. The prestigious event convened over 3,600 global exhibitors and more than 100,000 industry professionals to discuss the future landscape of pharmaceutical development.

As a leading manufacturer of APIs and intermediates, Newland  delivered a standout performance at the exhibition. The company showcased its high-quality core product portfolio, comprehensive one-stop CDMO services, and cutting-edge green manufacturing technologies. Demonstrating robust technical capabilities and a commitment to service excellence, Newland Pharma garnered significant attention and drove high-value engagement with both domestic and international attendees were successfully held at Shanghai New International Expo Centre.

Featuring its APIs and intermediates, the company utilized the platform to spotlight its advanced CMO/CDMO service offerings. The exhibition offered a strategic overview of the company's vertically integrated industrial chain, which seamlessly connects chiral pharmaceutical intermediates, specialty APIs, and bespoke process development. This holistic display underscored the company’s distinct market advantages, specifically its ability to deliver a stable supply, advanced custom technology, and eco-friendly manufacturing solutions to the global pharmaceutical industry.

Over the course of the three-day event, we successfully demonstrated our market leadership while deepening our connection to the pulse of the pharmaceutical sector. Direct dialogues with upstream and downstream partners, alongside industry visionaries, allowed us to accurately map emerging demand trends across the anti-infective, specialty generic, and innovative drug landscapes. The intelligence gathered during these sessions will directly inform our future R&D iterations, pipeline planning, and strategic business upgrades, ensuring we remain ahead of market needs.

Looking to the future, Newland Pharma is dedicated to reinforcing its core leadership in the sectors of chiral pharmaceutical intermediates, specialty APIs, and customized CDMO services. By prioritizing process innovation alongside eco-friendly, automated manufacturing, the company aims to steadily expand its global market share on the strength of its robust production capacity. Committed to collaborative growth, Newland Pharma seeks to unite with international partners to establish a safe, agile, and sustainable pharmaceutical supply chain, contributing high-quality Chinese manufacturing innovations to the global healthcare ecosystem.